- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04156789
Obstructive Sleep Apnoea in Sarcoidosis (OSASA)
Obstructive Sleep Apnoea in Sarcoidosis: A Cross-sectional Observational Study
Sarcoidosis is a multisystemic granulomatous disease of unknown origin. Fatigue is a common problem in sarcoidosis affecting between 50% and 80% of patients, and thus represents a major impairment of their quality of life.
The findings of recent studies suggest a high prevalence of obstructive sleep apnoea (OSA) in patients with sarcoidosis, estimating a range from 17% to 67%. Pathomechanisms leading to this increased OSA prevalence are still unclear, yet likely to be multifactorial including sarcoid myopathy and neuropathy leading to impaired integrity of the upper airways as well as corticosteroid induced obesity.
While both diseases, Sarcoidosis and OSA, could lead to fatigue and excessive daytime sleepiness (EDS) the current managing strategies differ significantly. OSA patients are mostly treated with continuous positive airway pressure (CPAP) whereas sarcoidosis associated fatigue may require increased immunosuppressive therapy. Little is known about treatment of fatigue and sleepiness in patients suffering from both conditions.This study aims to close this knowledge gap and define prevalence of OSA in a swiss cohort with sarcoidosis patients.
Therefore, we plan a prospective, observational, controlled study to investigate the prevalence of sleepiness, fatigue, life quality and obstructive sleep apnoea in patients with Sarcoidosis.
Patients treated in the University Hospital Zurich due to sarcoidosis will be invited by letter to take part in this study. After confirmed consent and baseline assessments at the University Hospital Zurich, these patients will undergo a single night, in-home sleep study to assess possible OSA.
Sleepiness and fatigue specific questionnaires and in-home respiratory polygraphy (oRP) are obtained in all subjects. To assess inflammation status and other conditions connected to sleepiness like hypothyroidism and anaemia, sarcoidosis patients will undergo blood sampling.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Zürich, Switzerland, 8091
- University Hospital Zurich
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Sarcoidosis group: Subjects with a definite diagnosis of sarcoidosis according to international ATS and WASOG guideline
vs
Control group: matched control subjects without sarcoidosis
Description
Inclusion Criteria:
- Sarcoidosis group: Subjects with a definite diagnosis of sarcoidosis according to international ATS and WASOG guideline.
- Informed consent
- 18 years or above
- Control group: No sarcoidosis, no OSA
Exclusion Criteria:
- Moribund or severe disease prohibiting protocol adherence
- Continuous positive airway pressure treatment for OSA at baseline
- Use of oxygen therapy or home ventilation
- Physical or intellectual impairment precluding informed consent or protocol adherence
- Pregnant patients
Study Plan
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Sarcoidosis group
Subjects with a definite diagnosis of sarcoidosis according to international ATS and WASOG guideline
|
Sarcoidosis patients and control subjects will undergo one night of home sleep apnea testing using ApnoeaLinkTM Plus device (ResMed Corporation, Poway, Calif).
The device records the patient's nasal respiratory pressure signal as a surrogate of nasal flow, respiratory movements by a thoracic impedance belt, and finger pulse oximetry.
The results of the sleep study will be scored automatically with dedicated software (ResMed Corporation, Poway, Calif), and manually reviewed to ensure data accuracy.
|
Control group
Control subjects have no sarcoidosis and will be sex, age (± 3 years), height (± 20 cm), and weight (± 15 kg) matched to sarcoidosis patients.
|
Sarcoidosis patients and control subjects will undergo one night of home sleep apnea testing using ApnoeaLinkTM Plus device (ResMed Corporation, Poway, Calif).
The device records the patient's nasal respiratory pressure signal as a surrogate of nasal flow, respiratory movements by a thoracic impedance belt, and finger pulse oximetry.
The results of the sleep study will be scored automatically with dedicated software (ResMed Corporation, Poway, Calif), and manually reviewed to ensure data accuracy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Prevalence of OSA in sarcoidosis patients compared to matched controls
Time Frame: through one sleep study night
|
Conventional thresholds according to the American Academy of Sleep Medicine Task Force of AHI ≥5, ≥15 and ≥30 will be used to define mild, moderate and severe OSA respectively.
OSA prevalence will be compared between both groups.
|
through one sleep study night
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Apnoea-Hypopnea Index (AHI)
Time Frame: through one sleep study night
|
AHI will be compared between both groups.
|
through one sleep study night
|
Fatigue Severity Scale (FAS)
Time Frame: one day
|
FAS will be compared between both groups.
Score ranges from 10 to 50 points with 50 points presenting the most severe form of fatigue.
|
one day
|
Blood pressure
Time Frame: one day
|
Blood pressure will be compared between both groups.
|
one day
|
Lung function test
Time Frame: one day
|
Lung function tests will be compared between both groups.
|
one day
|
Puls wave analysis
Time Frame: one day
|
Applanation-derived augmentation index (AIx) will be compared between both groups.
|
one day
|
Interleukin-2 blood levels
Time Frame: one day
|
Association between Interleukin-2 blood levels and OSA severity (AHI) and excessive daytime sleepiness (ESS) in sarcoidosis will be assessed.
|
one day
|
Oxygen-Desaturation Index (ODI)
Time Frame: through one sleep study night
|
ODI will be compared between both groups.
|
through one sleep study night
|
Epworth Sleepiness Scale (ESS)
Time Frame: one day
|
ESS will be compared between both groups.
The test measures subjective sleepiness.
The scale ranges from 0 to 24 points.
More points indicate higher sleepiness.
|
one day
|
Functional outcomes of sleep questionnaire (FOSQ)
Time Frame: one day
|
FOSQ will be compared between both groups.
The score ranges from 5 to 20 points.
Higher scores indicate better functional status.
|
one day
|
Short-form-36 (SF-36)
Time Frame: one day
|
SF-36 will be compared between both groups.
The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section.
Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight.
The lower the score the more disability.
|
one day
|
Patient Health Questionnaire (PHQ) Module 9
Time Frame: one day
|
PHQ 9 will be compared between both groups.
The test results range between 0 and 27 points.
Higher scores indicate severe forms of depression.
|
one day
|
NoSAS-Score
Time Frame: one day
|
NoSAS-Score will be compared between both groups.
The score ranges from 0-17 points.
The patient has a high probability of sleep disordered breathing if he has a NoSAS-Score of 8 or higher.
|
one day
|
Heart rate
Time Frame: one day
|
Heart rate will be compared between both groups
|
one day
|
Neopterin blood level
Time Frame: one day
|
Association between Neopterin blood levels and OSA severity (AHI) and excessive daytime sleepiness (ESS) in sarcoidosis will be assessed.
|
one day
|
C-reactive protein (CRP) blood levels
Time Frame: one day
|
Association between CRP blood levels and OSA severity (AHI) and excessive daytime sleepiness (ESS) in sarcoidosis will be assessed.
|
one day
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Malcolm Kohler, Prof, University of Zurich
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019-01604
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fatigue
-
Bakulev Scientific Center of Cardiovascular SurgeryFoundation for the Support of Physical Culture and Sports BECOME A CHAMPION; Autonomous Non-Profit organization of additional education sports school BECOME A CHAMPIONNot yet recruitingEfficacy, Self | Fatigue, Mental | Fatigue; Muscle, Heart | Fatigue; CombatRussian Federation
-
Universita di VeronaUniversity of Southern CaliforniaCompletedDiet, Healthy | Fasting | Fatigue, Mental | Fatigue; Muscle, HeartItaly
-
University of ZurichRecruitingVocal FatigueSwitzerland
-
KU LeuvenCompleted
-
Société des Produits Nestlé (SPN)Maastricht University Medical CenterCompleted
-
University of Applied Sciences for Health Professions...University of Wisconsin, MilwaukeeCompleted
-
Taoyuan General HospitalCompleted
-
Alaa Yousri Mahmoud AtiaUnknownMuscle FatigueEgypt
-
University Hospital, Clermont-FerrandLaboratoire des Adaptations Métaboliques à l'Exercice en conditions Physiologiques...CompletedNeuromuscular FatigueFrance
-
Central Hospital, Nancy, FranceUniversity of Lorraine; Institut National de Recherche et de Sécurité, Nancy...Unknown
Clinical Trials on Home sleep apnea testing
-
Mayo ClinicItamar-Medical, Israel; Sleep Number CorporationRecruitingHeart Failure | Obstructive Sleep ApneaUnited States
-
Koç UniversityKoc Healthcare Istanbul American Hospital, Marmara University HospitalUnknownPneumonia | Obstructive Sleep Apnea | COVIDTurkey
-
University of Colorado, DenverNational Cancer Institute (NCI)WithdrawnObstructive Sleep Apnea | Squamous Cell Carcinoma of Head and NeckUnited States
-
The University of Hong KongRecruitingObstructive Sleep Apnea | Mild Cognitive Impairment | Subjective Cognitive ImpairmentHong Kong
-
Inspire Medical Systems, Inc.Completed
-
Beth Israel Deaconess Medical CenterCompletedAtrial Fibrillation | Obstructive Sleep Apnea | Cardiac ArrhythmiasUnited States
-
John H. Stroger HospitalActive, not recruitingObstructive Sleep ApneaUnited States
-
Sunnybrook Health Sciences CentreUnity Health TorontoActive, not recruitingObstructive Sleep Apnea | Alzheimer Disease | Mild Cognitive Impairment | Vascular Dementia | Dementia With Lewy Bodies | Mixed Dementia | Parkinsons Disease With DementiaCanada
-
Sunnybrook Health Sciences CentreWomen's College HospitalRecruitingHypertension | Obstructive Sleep ApneaCanada
-
Centre Hospitalier Universitaire VaudoisUnknownObstructive Sleep Apnea | End Stage Renal DiseaseSwitzerland